ArticleCell biochemistry and biophysics2025
PCBP2 Promotes NRG4 mRNA Stability to Diminish Angiotensin II-Induced Hypertrophy, NLRP3 Inflammasome Activation, and Oxidative Stress of AC16 Cardiomyocytes.
Article in Cell biochemistry and biophysics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- RNA-Binding Proteins in Adipose Biology: From Mechanistic Understanding to Therapeutic Opportunities.International journal of molecular sciences · 2026Review
- Beyond Leptin and Adiponectin: The Diverse Roles of Adipokines in the Myocardial Hypertrophic Process and Heart Failure and Their Potential Contribution in Obesity.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Myocardial hypertrophy, a complex cardiovascular disorder, remains a significant challenge. NRG4 has shown protective effects against myocardial damage. Here, we clarified the role of NRG4 in angiotensin II (Ang II)-induced hypertrophy of AC16 cardiomyocytes. The Ang II-stimulated AC16 cell line was used as an in vitro model of myocardial hypertrophy. Immunofluorescence using an anti-α-actinin antibody was used to observe cell area and size. mRNA expression was detected by quantitative PCR, and protein levels were measured by immunoblot assay. ROS amount detection was performed by flow cytometry. The cell protein/DNA ratio and the levels of IL-1β, IL-18, MDA and SOD were tested using commercial kits. The relationship between PCBP2 and NRG4 mRNA was validated by luciferase, RNA immunoprecipitation (RIP), and mRNA stability assays. In Ang II-stimulated AC16 cells, PCBP2 and NRG4 were markedly downregulated. Increased NRG4 expression relieved Ang II-induced hypertrophy and fibrosis in AC16 cardiomyocytes. Moreover, NRG4 increase weakened NLRP3 inflammasome activation and oxidative stress in Ang II-stimulated AC16 cardiomyocytes. Mechanistically, PCBP2 stabilized NRG4 mRNA to increase NRG4 protein expression in Ang II-induced AC16 cardiomyocytes. NRG4 depletion counteracted the suppressive effects of PCBP2 upregulation on hypertrophy, NLRP3 inflammasome activation, and oxidative stress of Ang II-induced AC16 cardiomyocytes. Additionally, the PCBP2/NRG4 cascade regulated the AMPK/mTOR signaling pathway in Ang II-induced AC16 cardiomyocytes. Our data demonstrate that the previously uncharacterized PCBP2/NRG4 cascade attenuates Ang II-triggered hypertrophy, NLRP3 inflammasome activation, and oxidative stress of AC16 cardiomyocytes.
Indexed as
Identifiers
40679765What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.